Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Trump said Cook made a "good case" that it would be difficult for Apple to pay tariffs, when Samsung does not face the same hurdle because much of its manufacturing is in...Technologyread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
"I don't want to do business at all because it is a national security threat," Trump told reporters.Technologyread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Trump's is due to visit Copenhagen early next month, when the Arctic will be on the agenda in meetings.World Politicsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
CNBC reported Wednesday that Sam Waksal will step aside as chief executive of closely held Kadmon as the company plans to file for an initial public offering. Because of Waksal's ban from serving as an officer of a public company that stemmed from his insider trading charges, his brother, Harlan, is joining the company as president and CEO.
Kadmon confirmed the news in a press release, also noting Sam Waksal would remain chairman, "and will transition from that role in the event that the company elects to pursue an initial public offering."
The two brothers founded and ran ImClone together, with Sam as CEO and Harlan as chief operating officer, among other roles. At Kadmon, Sam will become chief of innovation, science and strategy.
"As we look to the future, it is my goal to ensure that the company is well-positioned to take advantage of value-building corporate, strategic and financial options," Harlan Waksal said in the company's statement.
Kadmon, which is developing drugs for cancer and other diseases, has raised about $500 million in debt and equity. A potential IPO comes amid a record streak in the biotech industry, and investors are likely to have an appetite for the company, said Les Funtleyder, portfolio manager with Esquared Asset Management and author of the book Healthcare Investing.
"Given how well the market's been receiving health-care IPOs this year, especially with late-stage assets, and Kadmon certainly has a fair share of late-stage assets, I think the market would be very receptive to a company like this," Funtleyder said. "ImClone was a very successful company; they brought a cancer drug to market that has actually helped people."
ImClone developed the cancer drug Erbitux, which was approved in 2004 after a rocky development path. It was the rejection of the drug's application by the FDA, in 2001, that was the source of the insider trading scandal involving both Waksal and Stewart. ImClone was sold to Eli Lilly in 2008 for $6.5 billion.
Read MoreShort sellers aiming at biotech
"Given his track record and given the desire for new drugs coming to market, I'd say investors are certainly willing to give him a chance," Funtleyder said. "Certainly the more financial-minded will remember ImClone ultimately got acquired by Lilly; it was very successful and a lot of people made money."
That doesn't mean the path to market won't be complicated.
"It's reasonable to expect that in the comment process of going public, there will be a lot of questions from the SEC about Mr. Waksal's going-forward role and the independence that his brother will exercise in the executive capacity in which he will serve," said Jacob Frenkel, chair of the securities enforcement, white-collar crime and government investigations practice at law firm Shulman, Rogers. "This will be scrutinized."